Capital Group Private Client Services Inc. Sells 5,822 Shares of Abbott Laboratories $ABT

Capital Group Private Client Services Inc. trimmed its position in shares of Abbott Laboratories (NYSE:ABT) by 2.4% during the 4th quarter, HoldingsChannel.com reports. The firm owned 231,893 shares of the healthcare product maker’s stock after selling 5,822 shares during the quarter. Capital Group Private Client Services Inc.’s holdings in Abbott Laboratories were worth $29,054,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in the company. American National Bank of Texas grew its holdings in Abbott Laboratories by 2.4% during the 4th quarter. American National Bank of Texas now owns 3,408 shares of the healthcare product maker’s stock valued at $427,000 after purchasing an additional 79 shares during the last quarter. Nia Impact Advisors LLC grew its stake in Abbott Laboratories by 2.2% in the 2nd quarter. Nia Impact Advisors LLC now owns 3,706 shares of the healthcare product maker’s stock worth $504,000 after acquiring an additional 79 shares in the last quarter. Connable Office Inc. grew its stake in Abbott Laboratories by 0.5% in the 3rd quarter. Connable Office Inc. now owns 15,042 shares of the healthcare product maker’s stock worth $2,015,000 after acquiring an additional 81 shares in the last quarter. Park Place Capital Corp grew its stake in Abbott Laboratories by 11.0% in the 4th quarter. Park Place Capital Corp now owns 815 shares of the healthcare product maker’s stock worth $102,000 after acquiring an additional 81 shares in the last quarter. Finally, Lantern Wealth Advisors LLC grew its stake in Abbott Laboratories by 1.7% in the 3rd quarter. Lantern Wealth Advisors LLC now owns 5,028 shares of the healthcare product maker’s stock worth $674,000 after acquiring an additional 84 shares in the last quarter. 75.18% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Argus dropped their target price on shares of Abbott Laboratories from $140.00 to $125.00 and set a “buy” rating on the stock in a research note on Tuesday, April 21st. Barclays dropped their target price on shares of Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating on the stock in a research note on Monday, April 20th. Sanford C. Bernstein dropped their target price on shares of Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating on the stock in a research note on Friday, April 17th. Leerink Partners dropped their target price on shares of Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating on the stock in a research note on Tuesday, April 21st. Finally, Daiwa Securities Group downgraded shares of Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 target price on the stock. in a research note on Wednesday, April 22nd. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $119.09.

Insider Buying and Selling

In other news, CFO Philip P. Boudreau bought 2,200 shares of the stock in a transaction on Thursday, April 23rd. The stock was bought at an average cost of $91.50 per share, for a total transaction of $201,300.00. Following the completion of the purchase, the chief financial officer directly owned 2,200 shares in the company, valued at approximately $201,300. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Daniel J. Starks bought 10,000 shares of the stock in a transaction on Monday, April 27th. The stock was purchased at an average price of $92.65 per share, with a total value of $926,500.00. Following the completion of the purchase, the director owned 6,751,103 shares of the company’s stock, valued at $625,489,692.95. This represents a 0.15% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Corporate insiders own 0.46% of the company’s stock.

Abbott Laboratories Price Performance

NYSE ABT opened at $91.20 on Friday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39. The firm’s 50 day moving average price is $92.80 and its 200-day moving average price is $109.31. Abbott Laboratories has a 52-week low of $81.97 and a 52-week high of $139.06. The company has a market cap of $158.85 billion, a PE ratio of 25.55, a P/E/G ratio of 1.52 and a beta of 0.63.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.14 by $0.01. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The firm had revenue of $11.16 billion for the quarter, compared to the consensus estimate of $10.99 billion. During the same period last year, the firm earned $1.09 earnings per share. The company’s quarterly revenue was up 7.8% on a year-over-year basis. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Sell-side analysts forecast that Abbott Laboratories will post 5.48 EPS for the current fiscal year.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.